CeriBell (NASDAQ:CBLL) Trading Up 4.5% - What's Next?

Shares of CeriBell (NASDAQ:CBLL - Get Free Report) were up 4.5% during mid-day trading on Monday . The stock traded as high as $16.00 and last traded at $16.00. Approximately 136,379 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 271,881 shares. The stock had previously closed at $15.31.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $32.50.

CeriBell Trading Up 0.2 %

The stock's 50 day moving average price is $18.85.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. Equities research analysts expect that CeriBell will post -2.46 EPS for the current year.

Insider Buying and Selling at CeriBell

In other news, CEO Xingjuan Chao sold 5,700 shares of the firm's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total transaction of $85,614.00. Following the completion of the sale, the chief executive officer now owns 746,451 shares in the company, valued at approximately $11,211,694.02. This trade represents a 0.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 24,700 shares of company stock worth $372,434 over the last ninety days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA grew its position in shares of CeriBell by 0.4% in the first quarter. Massachusetts Financial Services Co. MA now owns 416,908 shares of the company's stock valued at $8,009,000 after purchasing an additional 1,547 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in CeriBell in the 1st quarter valued at $10,312,000. New York State Common Retirement Fund bought a new position in CeriBell during the 1st quarter worth $67,000. Bank of New York Mellon Corp lifted its holdings in shares of CeriBell by 42.3% during the first quarter. Bank of New York Mellon Corp now owns 34,542 shares of the company's stock worth $664,000 after buying an additional 10,268 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of CeriBell by 26.5% in the first quarter. Rhumbline Advisers now owns 15,629 shares of the company's stock valued at $300,000 after acquiring an additional 3,276 shares during the period.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.